Albertsons Companies, Inc. Q3 FY2026 earnings call

• Strategic Turnaround & Leadership: Executive Chair Meg Whitman and CEO Susan Morris emphasized that performance has fallen short of potential. The company is initiating a comprehensive business review to accelerate progress, simplify operations, and improve shareholder returns.
• Organizational Simplification: Management acknowledged excessive complexity from too many overlapping initiatives over the last 18 months. The focus is shifting to fewer, high-impact projects with stricter accountability. ACI Edge is being accelerated, moving from 11 divisions to four regions and centralizing center-store merchandising.
• Cost Reduction Initiatives: The cost savings target has been increased from $1.5 billion to $2 billion over three years. Management identified significant additional opportunities in third-party spend (goods for resale and non-resale), SG&A headcount reduction, and store execution improvements, specifically targeting inventory discipline and shrink reduction.
• Customer Value Proposition: The strategy focuses on 'surgical' price investments rather than broad-based cuts. Priority areas include own brands, fresh differentiation, loyalty programs, and retail media. The goal is to deliver better value through personalized offers and improved store conditions.
• Portfolio Optimization: Albertsons is evaluating its asset portfolio to exit underperforming areas and double down on markets where it holds #1 or #2 market share. Decisions will be part of the comprehensive plan announced later in the year.
• Technology & AI: AI remains critical, with four 'big bets': Merch Intelligence for smarter category/price decisions, Store Labor optimization, Demand Forecasting for inventory/in-stock results, and general productivity enhancements.

The company reported second-quarter identical sales declining by 0.8%. Key operational highlights include e-commerce sales growing by 11% with digital penetration reaching 10.5%, and pharmacy script counts showing strong growth despite headwinds from the Inflation Reduction Act (IRA) and a shift from branded to generic prescriptions. Gross margin decreased by 17 basis points year-over-year to 26.8% (excluding fuel and LIFO), driven by e-commerce mix shifts, higher shrink associated with a cyclospora outbreak, and favorable rate impacts from lower IRA-related pharmacy sales. Adjusted EBITDA was $784 million, and adjusted EPS was $0.36 per diluted share. Selling, General, and Administrative (SG&A) expense rates increased by 38 basis points year-over-year due to sales deleveraging.

• No Incremental Update: Management declined to provide an incremental financial outlook update for the remainder of fiscal 2026, stating that current performance aligns with revised guidance expectations but that ongoing strategic reviews may alter investment pace and cost reduction timing.
• Future Roadmap: A comprehensive turnaround plan, including a refreshed customer strategy, expanded productivity program, pricing framework, portfolio optimization actions, and an updated capital allocation framework, will be presented at the fourth-quarter earnings call.
• Investor Day: An investor day is planned for spring 2027 to further detail these plans.
• Capital Allocation: The company maintains a disciplined approach, having repurchased approximately $400 million in shares during the first half of 2026, with $1.7 billion remaining against a $2 billion authorization. Dividends remain steady at $0.17 per share.

• Operational Headwinds: Significant negative impacts from the cyclospora outbreak affecting produce sales (shrink and unit impact) and egg deflation. Pharmacy sales face structural headwinds from the Inflation Reduction Act (120 bps) and the brand-to-generic prescription mix shift (30 bps).
• Consumer Pressure: Customers, particularly lower-income demographics, remain under pressure from elevated fuel prices and stubborn inflation, leading to trading down and reduced traffic/units.
• Execution Complexity: The buildup of competing initiatives and organizational layers has slowed decision-making and increased costs, posing a risk to effective execution if not simplified promptly.
• Litigation Uncertainty: Ongoing litigation against Kroger presents potential financial liabilities, though management stated current planning proceeds without effect on litigation outcomes.

Q: Why now for the comprehensive business review given recent ACI Edge announcements, and how does this impact ACI Edge's scope? / A: Susan Morris explained that the review is an evolution of ACI Edge aimed at moving faster and more aggressively. She admitted that previous initiatives created unnecessary complexity and competing priorities. Going forward, only initiatives that directly drive customer experience, financial performance, or cost/complexity removal will continue; others are paused. ACI Edge’s core elements, like centralized buying, are actually accelerating as they show early success.

Q: How much room is left for cost savings, and how is the balance between speed and risk managed? / A: Management believes there is substantial 'blue sky' for cost reductions in three key areas: goods for resale (via centralized buying), goods not for resale (aggregating demand across the $80B company), and SG&A (further headcount reductions). Speed is balanced by focus; by concentrating on fewer initiatives, the team can execute with greater clarity and impact, avoiding conflicting priorities.

Q: What is the strategy for pricing and value perception, and how will it be implemented? / A: The goal is not to be the cheapest but to offer a balanced, data-driven value proposition unique to each market. Pricing changes will be 'surgical'—strategic investments in specific categories and markets rather than broad-based reductions. This approach leverages the loyalty program for personalized offers. Detailed metrics and a full pricing framework will be shared at the Q4 earnings call.

Q: Is the business review dependent on the outcome of the Kroger litigation trial? / A: No. Management explicitly stated that the turnaround plan and cost-out initiatives are proceeding regardless of litigation outcomes. They are focusing on holistic capital allocation and operational improvements based on current business needs, not contingent on legal settlements.

Q: How is technology, specifically AI, supporting the turnaround efforts? / A: AI is integral to the strategy through four 'big bets': Merch Intelligence for assortment and pricing decisions, Store Labor optimization, Demand Forecasting to improve in-stock levels and inventory, and general productivity tools. These technologies are already being deployed to support store standards, customer value, and cost reduction, rather than waiting for future infrastructure upgrades.